Sensei Biotherapeutics Inc. presented new data on Solnerstotug, a potential first-in-class monoclonal antibody targeting VISTA, an immune checkpoint protein associated with immunosuppression in tumors. Solnerstotug is designed to bind selectively to VISTA within the acidic tumor microenvironment while minimizing binding in peripheral and normal tissues, addressing toxicity and pharmacokinetic challenges seen with first-generation VISTA-targeted antibodies. Preclinical data suggest that Solnerstotug rapidly accumulates in tumors and may offer an improved safety profile compared to earlier approaches. You can access the full presentation through the link below.